Precipio, Inc., a healthcare solutions company, provides diagnostic products, reagents, and services in the United States. It provides diagnostic blood cancer testing services. The company offers IV-Cell, a proprietary cell culture media that enables simultaneous culturing of four hematopoietic cell lineages; HemeScreen, a suite of robust genetic diagnostic panels; ICE-COLD PCR, a proprietary and patented specimen technology that increases the sensitivity of molecular based tests; and COVID-19 antibody tests. It sells ICE-COLD-PCR technology kits to bio-pharma customers. Precipio, Inc. has collaborations with academic institutions specializing in cancer research, diagnostics, and treatment. The company is based in New Haven, Connecticut.
Company profile
Ticker
PRPO
Exchange
Website
CEO
Mr. Ilan Danieli
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Ault Global Holdings, Inc., BitNile Holdings, Inc., DIGITAL POWER CORP, DPW Holdings, Inc.
SEC CIK
Corporate docs
Subsidiaries
Precipio Diagnostics, LLC • Precipio SPV, Inc. • CB4Cancer, LLC ...
IRS number
911789357
PRPO stock data
Latest filings (excl ownership)
8-K
Departure of Directors or Certain Officers
6 Sep 24
8-K
Precipio Announces Q2-2024 Shareholder Update Call
15 Aug 24
10-Q
2024 Q2
Quarterly report
13 Aug 24
8-K
Submission of Matters to a Vote of Security Holders
25 Jun 24
DEFA14A
Additional proxy soliciting materials
13 Jun 24
DEFA14A
Additional proxy soliciting materials
13 Jun 24
10-Q
2023 Q3
Quarterly report
14 May 24
8-K
Precipio Secures a short-term $500K Credit Facility
6 May 24
8-K
Termination of a Material Definitive Agreement
1 May 24
ARS
2023 FY
Annual report to shareholders
29 Apr 24
Transcripts
PRPO
Earnings call transcript
2024 Q2
19 Aug 24
PRPO
Earnings call transcript
2023 Q3
20 Nov 23
PRPO
Earnings call transcript
2023 Q2
17 Aug 23
PRPO
Earnings call transcript
2023 Q2
17 Aug 23
PRPO
Earnings call transcript
2023 Q1
17 May 23
PRPO
Earnings call transcript
2022 Q4
3 Apr 23
PRPO
Earnings call transcript
2022 Q3
14 Nov 22
PRPO
Earnings call transcript
2022 Q2
16 Aug 22
PRPO
Earnings call transcript
2021 Q4
4 Apr 22
PRPO
Earnings call transcript
2021 Q3
16 Nov 21
Latest ownership filings
4
Christina Rizopoulos Valauri
17 Oct 24
4
RICHARD A SANDBERG
17 Oct 24
4
Jeffrey Cossman
17 Oct 24
4
David Seth Cohen
17 Oct 24
4
RONALD ASBURY ANDREWS
17 Oct 24
4
David Seth Cohen
6 Sep 24
4
RONALD ASBURY ANDREWS
6 Sep 24
4
KATHLEEN LAPORTE
6 Sep 24
4
RICHARD A SANDBERG
6 Sep 24
4
Jeffrey Cossman
6 Sep 24
Financial summary
Quarter (USD) | Jun 24 | Mar 24 | Dec 23 | Sep 23 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 1.28 mm | 1.28 mm | 1.28 mm | 1.28 mm | 1.28 mm | 1.28 mm |
Cash burn (monthly) | (no burn) | 107.83 k | 406.67 k | 319.08 k | (no burn) | 79.08 k |
Cash used (since last report) | n/a | 404.92 k | 1.53 mm | 1.20 mm | n/a | 296.96 k |
Cash remaining | n/a | 874.08 k | -248.05 k | 80.83 k | n/a | 982.04 k |
Runway (months of cash) | n/a | 8.1 | -0.6 | 0.3 | n/a | 12.4 |
Institutional ownership, Q2 2024
8.8% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 12 |
Opened positions | 2 |
Closed positions | 1 |
Increased positions | 3 |
Reduced positions | 3 |
13F shares | Current |
---|---|
Total value | 671.42 mm |
Total shares | 129.99 k |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Kennedy Capital Management | 41.89 k | $217.43 mm |
Vanguard | 29.03 k | $150.69 mm |
BLK BlackRock | 28.91 k | $150.05 mm |
Geode Capital Management | 15.16 k | $76.95 mm |
Susquehanna International | 13.21 k | $67.03 mm |
UBS UBS | 615.00 | $3.19 mm |
WFC Wells Fargo & Company | 550.00 | $2.86 mm |
Tower Research Capital | 485.00 | $2.52 mm |
Advisor | 113.00 | $586.00 k |
BAC Bank of America | 11.00 | $57.00 k |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
15 Oct 24 | Andrews Ronald Asbury | Common Stock | Grant | Acquire A | No | No | 6.62 | 1,510 | 10.00 k | 11,128 |
15 Oct 24 | Cohen David Seth | Common Stock | Grant | Acquire A | No | No | 6.62 | 1,982 | 13.12 k | 47,560 |
15 Oct 24 | Cossman Jeffrey | Common Stock | Grant | Acquire A | No | No | 6.62 | 1,586 | 10.50 k | 12,312 |
15 Oct 24 | Christina Rizopoulos Valauri | Common Stock | Grant | Acquire A | No | No | 6.62 | 1,472 | 9.74 k | 5,021 |
15 Oct 24 | Sandberg Richard A | Common Stock | Grant | Acquire A | No | No | 6.62 | 2,492 | 16.50 k | 18,525 |